FDA Drug Recalls

Recalls / Class III

Class IIID-691-2013

Product

Nicardipine Hydrochloride Injection 25 mg/10 mL (2.5 mg/mL), 10 mL single-use vials, Rx Only, Mfd. by Exela Pharma Sciences, LLC, Lenoir, NC, Dist. by: West-ward Pharmaceutical Corp., Eatontown, NJ --- NDC 0143-9689-10

Brand name
Nicardipine Hydrochloride
Generic name
Nicardipine Hydrochloride
Active ingredient
Nicardipine Hydrochloride
Route
Intravenous
NDCs
0143-9633, 0143-9689, 0143-9634
FDA application
NDA022276
Affected lot / code info
Lot PLNJ1201 APRIL 2014 Lot PLNJ1202 MAY 2014

Why it was recalled

Failed Impurity/Degradation Specifications; out of specification value for impurity Nitrophenylpuridine Derivative (NPP-D)

Recalling firm

Firm
West-ward Pharmaceutical Corp.
Manufacturer
Hikma Pharmaceuticals USA Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
465 Industrial Way W, N/A, Eatontown, New Jersey 07724-2209

Distribution

Quantity
Lot PLNJ1201 -16,880 vials ; Lot PLNJ1202 - 16,960 vials
Distribution pattern
Nationwide

Timeline

Recall initiated
2013-05-13
FDA classified
2013-07-11
Posted by FDA
2013-07-17
Terminated
2015-03-17
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-691-2013. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class III recall: Nicardipine Hydrochloride · FDA Drug Recalls